Participation in school and physical education in juvenile idiopathic arthritis in a Nordic long-term cohort study

Table 2 Characteristics of 274 children in the Nordic JIA cohort according to school absence at the eight-year study visit^a

Characteristics at the eight-year visit	n	Absence ≤1 day (n = 228)	Absence > 1 day (n = 46)	OR (95% CI)	P-value
Female, n (%)	274	148 (64.9)	32 (69.6)	1.2 (0.6–2.4)	0.545
Age disease onset, years	274	5.2 (2.3–9.2)	4.6 (2.3–8.7)	1.0 (0.9–1.1)	0.440
BMI	234	19.5 (17.3–21.6)	19.8 (17.2–24.8)	1.1 (1.0–1.2)	0.117
Cumulative joint count	274	5 (2–10)	11 (5–14)	1.0 (1.0–1.0)	0.007
Active joints	274	0 (0–0)	0 (0–1)	1.5 (1.2–1.9)	0.002
Physician GA	190	0.0 (0.0–0.5)	1.0 (0.2–2.1)	7.1 (2.7–18.5)	< 0.001
Patient/parent GA	213	0.0 (0.0–0.6)	1.2 (0.0–2.5)	3.5 (1.8–6.8)	< 0.001
Pain VAS	217	0.0 (0.0–0.8)	1.4 (1.0–3.5)	3.5 (1.9–6.5)	< 0.001
CHAQ	274	0.0 (0.0–0.0)	0.3 (0.0–0.6)	10.1 (4.4–23.1)	< 0.001
CHQ-PF50, PhS	159	53.4 (47.9–57.3)	41.8 (32.1–50.4)	0.9 (0.8–0.9)	< 0.001
CHQ-PF50, PsS	159	54.9 (47.5–60.1)	54.3 (49.7–58.4)	1.0 (0.9–1.1)	0.792
DMARDs, n (%)	274	72 (31.6)	27 (58.7)	1.8 (1.3–2.7)	0.002
JADAS10	174	0.4 (0.0–2.2)	3.5 (0.6–6.1)	1.3 (1.2–1.5)	< 0.001
Not in remission, n (%)	267	126 (56.8)	42 (93.3)	10.7 (3.2–35.5)	< 0.001
ESR mm/hour	193	7.0 (4.0–11.0)	8.0 (4.0–13.0)	1.0 (1.0–1.1)	0.110
CRP mg/liter	201	0.0 (0.0–5.0)	0.0 (0.0–5.0)	1.0 (1.0–1.1)	0.168
RF positive	147	3 (2.6)	2 (6.3)	2.5 (0.4–15.6)	0.330
HLA-B27 positive	264	45 (20.6)	15 (32.6)	1.9 (0.9–3.7)	0.081
ANA positive	273	57 (25.1)	7 (15.2)	0.5 (0.2–1.3)	0.154

^aPatient-/ proxy-reported school absence because of JIA during the preceding 2 months of the eight-year study visit with univariate logistic regression. Values are the median (interquartile range, IQR), unless indicated otherwise, OR Odds ratio, CI Confidence interval, GA Global assessment, VAS Visual analogue scale, CHAQ Childhood health assessment questionnaire, CHQ-PF50 Child health questionnaire parent form, PhS Physical summary score, PsS Psychological summary score, DMARDs Disease-modifying antirheumatic drugs including biologics used at the final study visit, Not in remission Not in remission off medication according to the Wallace preliminary criteria [21], ESR Erythrocyte sedimentation rate, CRP C-reactive protein, RF Rheumatoid factor, assessed twice with at least 3 months interval, HLA-B27 Human leucocyte antigen, ANA Antinuclear antibody, assessed twice with at least 3 months interval

ISSN: 1546-0096